United Kingdom Fujifilm Expands its Advanced Therapies CDMO Business with Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. The MarketWatch News Department was not involved in the creation of this content. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Atara Biotherapeutics Enters Strategic Manufacturing - BioSpace The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies global network, which is a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO). For more information, go to: www.fujifilmdiosynth.com. Alex Chapman Christina Vad - American Management Association - LinkedIn Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell . To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. +1 919 337 4400, Belasis Avenue ehyllengren@atarabio.com FUJIFILM Diosynth Biotechnologies will retain 134 employees in manufacturing and quality positions at the site. Pipeline, Stories of The parties will also enter a long-term supply agreement, which could extend to ten years. Article Summary FUJIFILM has acquired the facility from Atara Biotherapeutics which is located in Thousand Oaks, California. ft. manufacturing facility is currently named Atara T-cell Operations and Manufacturing (ATOM) and is readily expandable to support cell therapy manufacturing processes, including allogeneic T-cell and CAR T immunotherapies. FREMONT, Calif., April 28, 2023 (PR Newswire Europe via COMTEX) -- FREMONT, Calif., April 28, 2023 /PRNewswire . United States of America For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress, Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty, Atara Biotherapeutics Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB). Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the potential commercial launch of tab-cel. Through this acquisition by FUJIFILM Corporation, FUJIFILM Diosynth Biotechnologies will solidify its leadership position as a complete solutions-manufacturing provider for advanced therapies. +1 979 431 3500, Biotek All 1 About FUJIFILM Diosynth Biotechnologies Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the potential commercial launch of tab-cel. About - T-Cell Immunotherapy Technology Platform - Atara Biotherapeutics We believe that now is the right time for a strategic relationship with FUJIFILM Diosynth Biotechnologies to give us access to the expert manufacturing capability Atara will require, when needed. Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. (Business Wire) Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Through this acquisition by FUJIFILM Corporation, FUJIFILM Diosynth Biotechnologies will solidify its leadership position as a complete solutions-manufacturing provider for advanced therapies. Thousand Oaks, CA. This acquisition is expected to be completed in April 2022, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Powered by Madgex Job Board Software, https://www.businesswire.com/news/home/20220401005459/en/, http://www.businesswire.com/news/home/20220401005459/en. Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the commercial launch of tab-cel. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business.. Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. Billingham, TS23 1LH . Its lead product includes Tab-cel (tabelecleucel), a T-cell . With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. The upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. For more information you can read our Privacy Policy. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Ataras T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California for USD 100 million upfront, retaining current manufacturing and quality staff at the site. Were the first company ever to receive an approval for an allogeneic T-cell immunotherapy. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. Global Multicancer Screening Market to Reach $7.78 Billion by 2032 in fighting diseaseto develop transformative therapies for patients with cancer and autoimmune conditions. Fujifilm to Acquire Ataras Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million, Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Product Manufacturing, Transaction Expected to Result in Reduced Operating Expenses for Atara, Upon Closing, Ataras Cash Expected to Fund Planned Operations into Q4 2023, Company to Host Live Conference Call and Webcast Today at 4pm PST / 7pm EST. Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing. Christine Jackman Alex Chapman Through this acquisition Fujifilm can extend its CDMO offering to advanced cell therapies. Excerpt: FUJIFILM Corporation announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. for USD 100 million. FUJIFILM Corporation will continue to expand its bio CDMO business by leveraging its strength of being able to handle a wide variety of biopharmaceutical process development and manufacturing from clinical to commercial scale for drug products, fill & finish, and packaging. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. Atara Biotherapeutics Announces the Completion of the Acquisition of Atara Biotherapeutics, Inc. ( @Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious. FDB will also expand use of the Thousand Oaks site and leverage its talented staff to manufacture a broader portfolio of cell therapies. Accordingly, we will further focus capital resources on the development and commercialization of our pipeline of potentially transformative therapeutics for serious diseases.. Thousand Oaks, CA 91320 This information is preliminary, has not been audited, and is subject to change upon the audit of the companys financial statements for the year ended December 31, 2021. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Ataras T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California for USD 100 million upfront, retaining current manufacturing and quality staff at the site. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc., (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . Studies, Expanded Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Growing our world-class talent and knowledge in manufacturing of advanced therapies is vital to our continued success in supporting our partners in advancing tomorrows medicines, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. Access. With the closing of the transaction, FUJIFILM Diosynth Biotechnologies will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. Atara Biotherapeutics, Inc.: , , For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. About FUJIFILM Corporation Eric Hyllengren Studies, Expanded Morrisville, NC 27560 FUJIFILM Diosynth Biotechnologies is a highly respected, quality-focused, industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, said Pascal Touchon, President and CEO of Atara.